Targeted Nucleoside Delivery Systems for Enhanced Therapeutic Efficacy

The present inventive concept relates to next-generation nucleoside delivery systems that leverage lipid or sphingolipid conjugation to enable targeted therapy for viral infections and cancer, thereby enhancing treatment efficacy and reducing side effects.

The original patent disclosed pharmaceutical compositions comprising substituted nucleotides and nucleosides for treating viral infections. However, these compositions had limited efficacy due to non-specific targeting, resulting in systemic toxicity and reduced therapeutic outcomes. The present inventive concept addresses this limitation by introducing targeted delivery systems that selectively direct nucleoside analogs to specific cells or tissues, thereby improving treatment outcomes and reducing adverse effects.

The inventive concept encompasses a range of targeted delivery systems, including lipid or sphingolipid conjugates, wherein the lipid or sphingolipid is modified to include a targeting moiety. These conjugates are designed to selectively deliver nucleoside analogs to specific cells or tissues, such as cancer cells or immune cells. The conjugates can be administered systemically or locally, depending on the desired therapeutic outcome. The inventive concept also includes methods for treating viral infections and cancer using these targeted delivery systems, as well as systems for personalized medicine that leverage a library of nucleoside analogs with tailored targeting moieties.

The present inventive concept is novel and non-obvious in its use of targeted lipid or sphingolipid conjugates to deliver nucleoside analogs, which overcomes the limitations of non-specific targeting in the original patent. The inventive concept's introduction of targeting moieties and its focus on personalized medicine represent a paradigm shift in the field of nucleoside-based therapies.

Alternative embodiments of the inventive concept may include the use of different types of targeting moieties, such as antibodies or aptamers, or the incorporation of additional functional groups to enhance targeting specificity. Variations of the inventive concept may also include the use of different nucleoside analogs or conjugation chemistries to expand the range of therapeutic applications.

The present inventive concept has significant commercial potential in the treatment of viral infections and cancer, with a projected market size of $10 billion by 2025. The targeted delivery systems and personalized medicine approaches enabled by this inventive concept are expected to revolutionize the field of nucleoside-based therapies, providing a competitive advantage to companies that adopt this technology.